SLRX — Salarius Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.20m
- -$1.01m
- 25
- 41
- 32
- 24
Annual cashflow statement for Salarius Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.35 | -12.8 | -31.6 | -12.5 | -5.58 |
| Depreciation | |||||
| Non-Cash Items | 0.061 | 0.514 | 11.6 | 0.655 | 0.274 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.04 | 2.03 | 2.37 | -0.968 | 0.772 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -10.3 | -10.2 | -17.6 | -12.8 | -4.53 |
| Capital Expenditures | -0.003 | 0 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | -1.5 | 0 | — |
| Sale of Business | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.003 | 0 | -1.5 | 0 | — |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 17.7 | 28.3 | 1.99 | 6.64 | 1.06 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.38 | 18.1 | -17.1 | -6.21 | -3.47 |